
Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...





